Clindamycin: Nursing Drug Guide, C. difficile Risk & NCLEX Review

Clindamycin is available as generic oral capsules and oral solution, and as clindamycin phosphate for IV or IM injection. Confirm the ordered formulation (hydrochloride oral vs phosphate parenteral) before administration.

Common brand names include Cleocin and Cleocin Phosphate (where stocked). Topical clindamycin products are separate orders—do not substitute without prescriber and pharmacy approval.

Clindamycin treats serious infections caused by susceptible anaerobic bacteria and susceptible streptococci, pneumococci, and staphylococci when penicillin is inappropriate (e.g., penicillin-allergic patients) per FDA labeling. Use should be reserved because of CDAD risk; consider less toxic alternatives such as erythromycin when suitable.

↔On a small screen, swipe or scroll sideways to see the full table.

Clindamycin does not treat viral upper respiratory infections. It should not be used for meningitis—drug does not diffuse adequately into cerebrospinal fluid per labeling.

Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S ribosomal subunit (bacteriostatic). Clindamycin phosphate is a prodrug converted to active clindamycin after IV or IM administration. Macrolide-inducible resistance can occur in some staphylococcal and beta-hemolytic streptococcal isolates—susceptibility testing and local resistance patterns matter.

Doses vary by infection severity, route, and formulation. Verify orders against current product labeling and pharmacy preparation instructions. If diarrhea occurs during therapy, discontinue clindamycin per boxed warning.

IV infusion (label examples): 300 mg in 50 mL over 10 min; 600 mg over 20 min; 900 mg over 30 min; 1,200 mg over 40 min. Concentration in diluent should not exceed 18 mg/mL; infusion rates should not exceed 30 mg/min. More than 1,200 mg in a single 1-hour infusion is not recommended.

Duration: For beta-hemolytic streptococcal infections, continue at least 10 days per labeling. Institutional protocols and product formulations may vary.

Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact prescriber or pharmacist for the next dose interval.

Pretreatment checks

• Allergy history: clindamycin, lincomycin (complete cross-resistance), and prior CDAD or severe antibiotic-associated colitis
• Complete medication reconciliation—neuromuscular blocking agents, strong CYP3A4 inhibitors/inducers (e.g., rifampicin per label)
• Baseline bowel pattern and recent antibiotic courses (including outpatient prescriptions)
• For IV: verify dilution, infusion rate, line patency, and that undiluted IV bolus is not ordered
• Confirm bacterial indication; obtain blood cultures when sepsis is suspected per protocol before antibiotics when feasible

Contraindications

• History of hypersensitivity to clindamycin or lincomycin
• Active treatment of nonbacterial infections (e.g., most uncomplicated upper respiratory viral illness) without appropriate indication

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Routes: Oral (capsules, solution), IM injection, or IV infusion after dilution. Parenteral products contain benzyl alcohol—consider neonatal/premature infant risk per labeling.

• Follow medication administration rights; verify formulation and concentration (e.g., 150 mg/mL phosphate for injection)
• IV: dilute before use; infuse over at least 10–60 minutes—never administer undiluted IV bolus per labeling
• Program IV infusion pump within institutional maximum rate (label: not faster than 30 mg/min)
• Inspect solution for particulate matter and discoloration before administration
• Document exact start/stop times; too-rapid IV administration has been associated with cardiopulmonary arrest and hypotension per label

• Defervescence and improving local infection signs (e.g., decreasing cellulitis spread, improving wound drainage character, reduced pleuritic pain) after 48–72 hours when organism is susceptible
• Stable vitals without new GI toxicity or hypersensitivity findings
• Culture or susceptibility results support continued therapy when available

Worsening diarrhea, abdominal distension, or leukocytosis with left shift may indicate CDAD rather than slow response—do not assume the patient needs a longer clindamycin course without prescriber review.

↔On a small screen, swipe or scroll sideways to see the full table.

Significant mortality was observed in animals at very high IV or oral doses (label reports include convulsions and depression in mice). There is no specific antidote listed in the reviewed prescribing information.

Management

• Discontinue clindamycin and provide supportive care
• Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from serum per labeling
• Contact local poison control or medical toxicology services per facility protocol for large overdoses or serious symptoms

• Clindamycin vs clonidine — similar syllables; verify full drug name on MAR and pump
• Clindamycin vs lincomycin — distinct agents but cross-allergy; do not substitute
• Oral vs IV formulation — phosphate injection must not be given orally; capsules are hydrochloride
• Undiluted IV bolus — never push clindamycin IV undiluted; use pharmacy-prepared infusion
• Rate errors — programming faster than 30 mg/min increases risk of hypotension and cardiopulmonary arrest per label

↔On a small screen, swipe or scroll sideways to see the full table.

Hold clindamycin and escalate when any of the following appear.

• Watery or bloody stools with abdominal cramping or fever—suspect CDAD (may occur during therapy or up to two months later)
• Hypotension, cardiopulmonary arrest, or severe flushing during or immediately after IV infusion—suspect rate-related reaction
• Anaphylaxis or severe hypersensitivity: urticaria, angioedema, bronchospasm, hypotension
• Severe skin reaction: blistering, mucosal involvement, widespread rash with systemic symptoms
• New leukopenia, jaundice, or oliguria during prolonged therapy—notify prescriber

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Stool frequency, consistency, and blood; abdominal distension and pain each shift
• Vital signs during IV infusion and for 30 minutes after—watch for hypotension
• Signs of clinical infection improvement (temperature, WBC trend, wound, respiratory status)
• Periodic liver and kidney function tests and blood counts during prolonged therapy per labeling
• Infant GI symptoms if patient is breastfeeding

Document

• Indication, culture data, and allergy verification (clindamycin/lincomycin)
• IV dilution volume, infusion duration, and pump rate; line site assessments
• Baseline and ongoing bowel pattern; any CDAD workup and isolation orders

• Antibiotics treat bacterial infections only—not colds or most sore throats caused by viruses
• Finish the course as directed unless you develop severe diarrhea, bloody stools, or allergic symptoms—then contact your clinician before the next dose
• Diarrhea can occur during therapy or up to two months after the last dose—report watery or bloody stools promptly
• Do not take antidiarrheal medicines for severe antibiotic-associated diarrhea unless your prescriber advises
• Tell all clinicians about clindamycin reactions so future antibiotic orders can be chosen safely

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for clindamycin with a tabbed case (MAR, labs, I&O, nursing notes), then priority action, SATA cue recognition, stool-trend interpretation, matrix urgency sorting, infusion-safety judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.